Diana Do, MD, of Stanford University, spoke at AAO 2025 about the first-time results from the ELARA study, which found that aflibercept 8 mg given every 4 weeks in eyes that had received prior anti-VEGF treatment was “meaningful and impactful.”
Diana Do, MD:
Hi. I am Dr. Diana Do, Vice Chair of Clinical Affairs and Professor of Ophthalmology at the Byers Eye Institute at Stanford University. At the American Academy of Ophthalmology Retina Sub-Specialty Day, I was able to present first-time results from the ELARA study. Recall that ELARA is a phase 3b ongoing clinical trial evaluating flexible dosing of aflibercept 8 mg in eyes that received prior anti-VEGF therapy for their neovascular age-related macular degeneration or their diabetic macular edema. These patients in this study received 7 monthly injections of aflibercept 8 mg from baseline to week 24. Thereafter, they were switched to a treat-and-extend regimen, so let’s see what the results showed.
First, in those eyes that had received prior anti-VEGF therapy for their wet AMD, when they were switched over to aflibercept 8 mg, they were able to gain an additional 2.3 letters, and this was accompanied by a reduction in retinal thickness, on average, of 32 microns.
For those eyes that received prior treatment for their diabetic macular edema, they gained nearly three letters of vision when switching over to aflibercept 8 mg, and they also had a reduction in the retinal thickness of another 50 microns. Furthermore, there were no safety signals associated with the frequent use of aflibercept 8 mg.
In summary, the ELARA top-line results from week 24 show that aflibercept 8 mg, given every 4 weeks in eyes that had received prior anti-VEGF treatment, was meaningful and impactful. It improved the vision in both wet AMD and DME eyes, and it caused additional reductions in retinal thickness. Thank you again for allowing me to share this information.
Related Content
